Efficacy of auriculotherapy in improving sleep quality in people living with HIV: a randomized clinical trial

niversidade Federal do Ceará0 个研究点开始时间: 2022年3月9日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•People living with HIV (PLHIV) aged 18 or over, of both sexes; On antiretroviral therapy (ART) for at least three months, a period stipulated based on the time the patient needs to adapt to the medication. According to the literature, from the first month onwards, initial adverse events are minimized, as in the case of the use of Efavirenz (EFV), which has acute effects on the central nervous system in up to 50% of patients in the first week of treatment, such as : dreams, nightmares, sadness, irritability, nervousness, dizziness and difficulty sleeping (NGUYEN et al., 2011; WATERS et al., 2011; SCOURFIELD et al., 2012; OSHINAIKE et al., 2014; ALLAVENA, 2015). Other antiretroviral drugs can also cause sleep disorders, such as Zidovudine (AZT), Stavudine (d4T), Lamivudine (3TC), Indinavir (Crixivam) (BRASIL, 2004); Complaints of poor sleep quality, confirmed by the Pittsburgh Sleep Quality Index (PSQI-BR), with scores greater than 10 (BUYSSE et al.; 1989; BERTOLAZI et al., 2011; FONSECA et al., 2010; ; KONRAD 2005); Availability for face-to-face return on the 8th and 15th days of the beginning of the intervention, and telephone assessment on the 22nd and 29th days of the intervention; Have your own landline or cell phone.

•Patients with disabling mental illness; pregnant women; Homeless people and those deprived of their liberty in penitentiaries; Dermatological lesion at the site of the auriculotherapy points of the study; Allergy to the material used in the intervention.

发起方

niversidade Federal do Ceará